Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Inhibrx Biosciences Inc (INBX)

160 + Investors. Track Smart Money conviction in INBX. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +30
Streak
1Q ▲
Buyers last Q
63%

Smart Money Signals — INBX

Based on 165 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds added INBX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
165 hedge funds hold INBX right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +88% more funds vs a year ago

fund count last 6Q
+77 new funds entered over the past year (+88% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟢

More buyers than sellers — 63% buying

113 buying67 selling
Last quarter: 113 funds were net buyers (53 opened a brand new position + 60 added to an existing one). Only 67 were sellers (44 trimmed + 23 sold completely). A clear majority buying is a strong confirmation signal.
📈

More new buyers each quarter (+31 vs last Q)

new funds entering per quarter
Funds opening a new INBX position: 25 → 47 → 22 → 53. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔒

43% of holders stayed for 2+ years

■ 43% conviction (2yr+) ■ 21% medium ■ 36% new
71 out of 165 hedge funds have held INBX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💰

Value +59% but shares only +18% — price-driven

Value
+59%
Shares
+17%
Last quarter: the total dollar value of institutional holdings rose +59%, but actual share count only changed +18%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
➡️

Steady discovery — ~53 new funds/quarter

9 → 25 → 47 → 22 → 53 new funds/Q
New funds entering each quarter: 25 → 47 → 22 → 53. Consistent flow of new institutional buyers without clear acceleration or slowdown.
🏛️

Veteran-anchored — 54% veterans vs 36% newcomers

■ 54% veterans ■ 10% 1-2yr ■ 36% new
Entry-cohort mix of 175 holders: 95 (54%) are 2+ year veterans, 17 entered 1–2 years ago, and 63 (36%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
✅

Strong quality — 39% AUM from major funds

39% from top-100 AUM funds
41 of 161 holders rank in the top 100 by AUM, accounting for 39% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
4.6
out of 10
Moderate Exit Risk
Exit risk score 4.6/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — INBX

In 2026 Q2, 113 hedge funds were net buyers of INBX (53 opened a new position, 60 added to an existing one), while 67 reduced or exited (44 trimmed, 23 sold completely) — a 63% buyer ratio, indicating clear institutional accumulation. 39% of total institutional value in INBX is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +30 funds (more new holders than closures). Total institutional holders: 165.

Hedge Fund Ownership: INBX

How many hedge funds hold INBX — quarterly history vs. share price
Quarterly hedge fund ownership of INBX vs. share price

Market Analysis: INBX

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: INBX

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Inhibrx Biosciences Inc (INBX) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much INBX has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 82d ago
INBX
+13.7%
XLV
+6.1%

INBX outperformed XLV by +7.6% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 37d ago
INBX
+21.9%
XLV
+0.6%

Since the filing became public, INBX outperformed XLV by +21.3% .

Interpretation: The stock has meaningfully outrun its sector. The trade has partially played out; entry is at a premium to the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

9 top-rated funds 2 high-conviction
Consensus
4.3
/ 10
breadth
×
Elite
2.7
/ 10
conviction
Hedge Fund Positioning: INBX
160 + Investors

Track Smart Money conviction in INBX. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q2) Prior (2026 Q1) Change
Funds Holding 160 135 18.52%
13F Shares 15M 13M 12.31%
Total Value $1.39B $878M 58.11%
New Positions 53 22 +31
Increased Positions 54 54 -
Closed Positions 24 27 -3
Reduced Positions 42 36 +6
Total Calls 10 10 -
Total Puts 4 3 33.33%
PUT/CALL Ratio 0.4 0.3 Bullish

Statistics: INBX

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

160 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in INBX. Verified SEC 13F-HR filings.

QUARTER:
Top 25 INBX holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Sanofi 20.54% 1,157,926 $109.7M
2 CDC Financial, Inc. 5.56% 140,130 $13.3M
3 PFM Health Sciences, LP 2.51% 308,385 $29.2M
4 Parkman Healthcare Partners LLC 2.49% 256,950 $24.3M
5 Perceptive Advisors LLC 1.85% 1,297,763 $123.0M
6 First Turn Management, LLC 1.67% 164,783 $15.6M
7 Cannon Global Investment Management, LLC 1.58% 5,900 $559K
8 Western Standard LLC 1.51% 47,000 $4.5M
9 Sofinnova Investments, Inc. 1.48% 303,103 $28.7M
10 CDC Financial, Inc. 1.19% 30,000 $2.8M
11 Hussman Strategic Advisors, INC. 0.69% 31,500 $3.0M
12 Ratan Capital Management LP 0.51% 16,612 $1.6M
13 Viking Global Investors LP 0.30% 1,123,929 $106.5M
14 Persium Advisors, LLC 0.30% 4,875 $462K
15 Atom Investors LP 0.25% 29,594 $2.8M
16 Schonfeld Strategic Advisors LLC 0.24% 697,586 $66.1M
17 Marble Bar Asset Management LLP 0.23% 3,537 $335K
18 Informed Momentum Co LLC 0.19% 23,077 $2.2M
19 Opaleye Management Inc. 0.17% 20,291 $1.9M
20 Platinum Investment Management Ltd 0.14% 6,146 $582K
21 ArrowMark Colorado Holdings LLC 0.14% 35,176 $3.3M
22 Woodline Partners LP 0.12% 400,892 $38.0M
23 Nicholas Investment Partners, LP 0.11% 21,443 $2.0M
24 Voleon Capital Management LP 0.10% 58,358 $5.5M
25 Harvest Management LLC 0.10% 2,600 $246K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Inhibrx Biosciences Inc (INBX)

What does the Smart Money Trend signal show for INBX?

Buying streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds added INBX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for INBX?

More buyers than sellers — 63% buying: Last quarter: 113 funds were net buyers (53 opened a brand new position + 60 added to an existing one). Only 67 were sellers (44 trimmed + 23 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for INBX holders?

Strong quality — 39% AUM from major funds: 41 of 161 holders rank in the top 100 by AUM, accounting for 39% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held INBX?

43% of holders stayed for 2+ years: 71 out of 165 hedge funds have held INBX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Inhibrx Biosciences Inc (INBX) following the 2026 Q2 hedge fund 13F filings?

As of today, INBX has moved +21.9% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.6% for the XLV sector ETF — an outperformance of +21.3%. Since the quarter end (June 30, 2026), INBX has gained +13.7% vs +6.1% for XLV. The stock has meaningfully outrun its sector. The trade has partially played out; entry is at a premium to the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →